Nektar Therapeutics Presents Positive REZOLVE-AD Study Data, Demonstrating Statistically Significant Improvements in Atopic Dermatitis Patients with a History of Asthma.

Nektar Therapeutics presented new data from its ongoing REZOLVE-AD Phase 2b study at the ACAAI 2025 Annual Scientific Meeting. The study showed statistically significant and clinically meaningful improvements in mean ACQ-5 scores for patients with atopic dermatitis and a history of asthma. Extended dosing with rezpegaldesleukin supported a 24-week induction period, with improvements across major efficacy endpoints from Week 16 to 24. Top-line Phase 2b data for rezpegaldesleukin in alopecia areata is expected in December 2025, and long-term maintenance data is expected in Q1 2026.